奥佐利珠单抗30mg对甲氨蝶呤应答不佳类风湿关节炎患者的早期效应:II/III期OHZORA试验的事后轨迹分析
基于OHZORA试验141例甲氨蝶呤应答不佳的类风湿关节炎患者,起始奥佐利珠单抗30mg后第3天低疾病活动度(CDAI)达标率为12.8%(n=18),第52周升至70.9%(n=100),52周药物留存率87.9%(n=124)。生长混合模型识别出3组轨迹,其中78例在4周内达LDA并维持至52周;多因素分析提示基线CRP和CDAI较低与组别归属独立相关。
要点
- 奥佐利珠单抗30mg治疗第3天CDAI-LDA达标率为12.8%(n=18)。
- 第52周CDAI-LDA达标率为70.9%(n=100),药物留存率87.9%(n=124)。
- 生长混合模型识别3组轨迹,78例在4周内达LDA并维持至52周。
核心结论
- 奥佐利珠单抗30mg对甲氨蝶呤应答不佳的类风湿关节炎患者显示出即时和持续的疗效。
- 多因素分析提示基线炎症和疾病活动度(以CRP和CDAI表示)可能独立影响治疗反应。
- 基线疾病活动度导致的残余混杂不能完全排除,是本研究的局限性。
研究设计与样本
- 基于II/III期OHZORA试验数据的事后轨迹分析,纳入141例甲氨蝶呤应答不佳的类风湿关节炎患者,起始奥佐利珠单抗30mg治疗。
- 主要指标为起始奥佐利珠单抗后第3天按CDAI达到低疾病活动度(LDA)的比率。
- 采用生长混合模型(GMM)分析CDAI轨迹。
主要发现
- 奥佐利珠单抗治疗至52周的留存率为87.9%(n=124)。
- 起始奥佐利珠单抗第3天的LDA达标率为12.8%(n=18),至第52周70.9%(n=100)改善至LDA。
- GMM识别出3个不同组别,其中一组(n=78)在起始奥佐利珠单抗4周内达到LDA并维持至第52周。
- 多因素logistic回归分析显示,基线CRP低和CDAI低均与组别归属独立相关。
局限性
- 基线疾病活动度导致的残余混杂不能完全排除,是本研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study assessed the early effects of ozoralizumab (OZR) 30 mg in patients with rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX-IR), drawing on OHZORA trial data for efficacy and safety insights. METHODS: The study included 141 patients with RA from the OHZORA trial, initiated on OZR 30 mg. The primary measure was the rate of achieving low disease activity (LDA) by the Clinical Disease Activity Index (CDAI) 3 days post-OZR initiation. Growth mixture modelling (GMM) of CDAI trajectories was performed to enable a more detailed analysis of the impact of OZR on disease activity improvement. RESULTS: The retention rate of OZR up to 52 weeks was 87.9% (n=124). The LDA achievement rate on the third day of OZR introduction was 12.8% (n=18), and by week 52, 70.9% (n=100) had improved to LDA. Three distinct groups were identified using GMM: one group (n=78) reached LDA within 4 weeks of OZR initiation and maintained LDA up to week 52. Multiple logistic regression analysis revealed that both low baseline C-reactive protein (CRP) and low CDAI were independently associated with group membership. CONCLUSION: OZR 30 mg demonstrated both immediate and sustained efficacy in MTX-IR patients with RA. Multivariate analysis suggested that both baseline inflammation and disease activity-represented by CRP and CDAI-may independently influence treatment response. However, residual confounding due to baseline disease activity cannot be completely excluded, and this remains a limitation of the present study.
引用
- Miyazaki Y, Horiuchi N, Okamoto S, et al. Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial. RMD Open. 2025. PMID: 40537275. doi:10.1136/rmdopen-2025-005710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。